|
Market Closed -
Nasdaq
16:00:00 2026-09-24 EDT
|
5-day change | 1st Jan Change | ||
| 1.920 USD | -4.95% |
|
+3.78% | +23.08% |
| 09-16 | Novartis halts ALS drug development after mid-stage trial failure | RE |
| 09-15 | Alector, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 07:00 AM |
Company Valuation: Alector, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,678 | 763.3 | 671.4 | 185.1 | 170.3 | 214.4 | - | - |
| Change | - | -54.52% | -12.04% | -72.43% | -8% | 25.9% | - | - |
| Enterprise Value (EV) 1 | 943.1 | 50.48 | 122.5 | -228.3 | -76.06 | -13.09 | -82.38 | -181.2 |
| Change | - | -94.65% | 142.74% | -286.3% | 66.69% | 82.79% | -529.51% | -119.99% |
| P/E | -45.9x | -5.7x | -5.12x | -1.54x | -1.12x | -2.23x | -2.9x | -2.56x |
| PBR | 5.63x | 3.57x | 4.98x | 1.48x | 5.62x | 7.68x | 4.09x | 2.7x |
| PEG | - | -0x | 1.38x | 0.1x | -0.1x | 0.1x | 0.1x | -0.2x |
| Capitalization / Revenue | 8.1x | 5.71x | 6.92x | 1.84x | 8.09x | 19.5x | 7.65x | 58.6x |
| EV / Revenue | 4.55x | 0.38x | 1.26x | -2.27x | -3.61x | -1.19x | -2.94x | -49.6x |
| EV / EBITDA | -30.4x | -0.38x | -0.84x | 1.64x | 0.51x | 0.12x | 0.68x | 1.3x |
| EV / EBIT | -25.2x | -0.37x | -0.81x | 1.57x | 0.49x | 0.12x | 0.75x | 1.5x |
| EV / FCF | 3.19x | -2.07x | -0.66x | 0.99x | 0.41x | 0.27x | 0.74x | 1.94x |
| FCF Yield | 31.3% | -48.4% | -152% | 101% | 242% | 369% | 135% | 51.7% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.45 | -1.62 | -1.56 | -1.23 | -1.39 | -0.862 | -0.6617 | -0.75 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 207.1 | 133.6 | 97.06 | 100.6 | 21.04 | 10.97 | 28.01 | 3.656 |
| EBITDA 1 | -31.03 | -132.1 | -146 | -139.6 | -150.3 | -112.7 | -121.1 | -138.9 |
| EBIT 1 | -37.36 | -137.8 | -151.7 | -145 | -156 | -108.8 | -110.1 | -120.7 |
| Net income 1 | -36.33 | -133.3 | -130.4 | -119 | -142.9 | -97.52 | -97.35 | -108.1 |
| Net Debt 1 | -735.3 | -712.9 | -548.9 | -413.4 | -246.3 | -227.5 | -296.8 | -395.6 |
| Reference price 2 | 20.650 | 9.230 | 7.980 | 1.890 | 1.560 | 1.920 | 1.920 | 1.920 |
| Nbr of stocks (in thousands) | 81,276 | 82,702 | 84,136 | 97,933 | 109,151 | 111,657 | - | - |
| Announcement Date | 2/24/22 | 2/28/23 | 2/27/24 | 2/26/25 | 2/25/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.35x | -0.18x | 0.02x | -.--% | 226M | |
| 21.81x | 7.74x | 15.55x | 1.36% | 74.18B | |
| 30.94x | 8.91x | 27.77x | 0.04% | 59.55B | |
| -72.24x | 13.96x | -67.31x | -.--% | 25.84B | |
| -15.16x | 5.72x | -7.19x | -.--% | 24.73B | |
| 28.65x | 5.38x | 17.91x | -.--% | 20.87B | |
| 44.32x | 16.25x | 32.97x | 0.34% | 15.32B | |
| 17.52x | 5.22x | 12.18x | -.--% | 14.06B | |
| -14.32x | 3225.89x | -16.49x | -.--% | 13.12B | |
| -81.25x | 7.42x | -61.47x | -.--% | 11.85B | |
| Average | -4.21x | 329.63x | -4.61x | 0.17% | 25.98B | |
| Weighted average by Cap. | 6.12x | 171.18x | 3.83x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ALEC Stock
- Valuation Alector, Inc.
Select your edition
All financial news and data tailored to specific country editions
